Therapy with low-dose interferon alfa improves non–human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS), especially nonaggressive forms, probably through a combination of antiangiogenic, antiviral, and immunomodulating effects.1,2 We report on a new onset of KS in an HIV-negative man undergoing therapy with interferon alfa-2a for cutaneous T-cell lymphoma (CTCL).
Giuliani M, Mastroianni A, Di Carlo A, et al. Onset of Non-AIDS Kaposi Sarcoma During Therapy With Interferon Alfa-2a in an 82-Year-Old Man With Concomitant Cutaneous T-Cell Lymphoma. Arch Dermatol. 2002;138(4):535–537. doi:10.1001/archderm.138.4.533
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: